Investigation of the mechanism involved in the As2O3-regulated decrease in MDR1 expression in leukemia cells

Gao,Feng; Liu,Jia; Dong,Wan Wei; Wang,Wei; Wang,Ying; Cai,Dali; Zheng,Zhihong; Sun,Kailai

doi:10.3892/or.2013.2930

Investigation of the mechanism involved in the As2O3-regulated decrease in MDR1 expression in leukemia cells

Authors:
- Feng Gao
- Jia Liu
- Wan Wei Dong
- Wei Wang
- Ying Wang
- Dali Cai
- Zhihong Zheng
- Kailai Sun
View Affiliations

Affiliations: Department of Genetics, China Medical University, Heping, Shenyang, Liaoning 110001, P.R. China, Laboratory Animal Center, China Medical University, Heping, Shenyang, Liaoning 110001, P.R. China, The First Hospital of China Medical University, Heping, Shenyang, Liaoning 110001, P.R. China
Published online on: December 16, 2013 https://doi.org/10.3892/or.2013.2930
Pages: 926-932

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Arsenic trioxide (As2O3) inhibits the expression of P-glycoprotein (P-gp) in leukemia cells; however, the mechanism behind this inhibition is unclear. The present study aimed to explore the effect of As2O3 on the expression and regulation of P-gp in leukemia cells, and elucidate the mechanism of the reversal of drug resistance. In the present study, electrophoretic mobility shift assay results indicated that p65 binds to the NF-κB binding site of MDR1, specifically in K562/D cells. Expression of p65 and phosphorylated IκB was reduced, while the expression of IκB was increased in K562/D cells treated with As2O3. The activity of luciferase increased up to 9-fold with 40 ng/ml TNF-α, and it was suppressed by ~25% following treatment with 1 µM As2O3. These findings suggest that As2O3 reverses the P-gp-induced drug resistance of leukemia cells through the NF-κB pathway. As2O3 may inhibit the activity of phosphorylase to inhibit IκB phosphorylation, thereby inhibiting NF-κB activity and MDR1 gene expression, leading to reversal of drug resistance.

View Figures

View References

1	Wang T, Ma LM, Zhang HP, Wang HW, Yang LH and Qiao ZH: The effect of arsenic trioxide (As₂O₃) combined with BSO on K562/ADM cells and its mechanisms. Zhonghua Xue Ye Xue Za Zhi. 28:438–443. 2007.(In Chinese).
2	Mathas S, Lietz A, Janz M, et al: Inhibition of NF-κB essentially contributes to arsenic-induced apoptosis. Blood. 102:1028–1034. 2003.
3	Thomas H and Coley HM: Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 10:159–165. 2003.PubMed/NCBI
4	Lee HR, Cheong HJ, Kim SJ, Lee NS, Park HS and Won JH: Sulindac enhances arsenic trioxide-mediated apoptosis by inhibition of NF-κB in HCT116 colon cancer cells. Oncol Rep. 20:41–47. 2008.PubMed/NCBI
5	Mathieu J and Besancon F: Arsenic trioxide represses NF-κB activation and increases apoptosis in ATRA-treated APL cells. Ann NY Acad Sci. 1090:203–208. 2006.
6	Park MJ, Lee JY, Kwak HJ, et al: Arsenic trioxide (As₂O₃) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-κB and reactive oxygen species. J Cell Biochem. 95:955–969. 2005.PubMed/NCBI
7	Bentires-Alj M, Barbu V, Fillet M, et al: NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 22:90–97. 2003.
8	Kuo MT, Liu Z, Wei Y, et al: Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-κB signaling. Oncogene. 21:1945–1954. 2002.
9	Tanigawara Y: Role of P-glycoprotein in drug disposition. Ther Drug Monit. 22:137–140. 2000. View Article : Google Scholar : PubMed/NCBI
10	Callen DF, Baker E, Simmers RN, Seshadri R and Roninson IB: Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum Genet. 77:142–144. 1987. View Article : Google Scholar : PubMed/NCBI
11	Scotto KW and Johnson RA: Transcription of the multidrug resistance gene MDR1: a therapeutic target. Mol Interv. 1:117–125. 2001.PubMed/NCBI
12	Hirsch-Ernst KI, Ziemann C, Schmitz-Salue C, Foth H and Kahl GF: Modulation of P-glycoprotein and mdr1b mRNA expression by growth factors in primary rat hepatocyte culture. Biochem Biophys Res Commun. 215:179–185. 1995.
13	Hirsch-Ernst KI, Ziemann C, Foth H, Kozian D, Schmitz-Salue C and Kahl GF: Induction of mdr1b mRNA and P-glycoprotein expression by tumor necrosis factor alpha in primary rat hepatocyte cultures. J Cell Physiol. 176:506–515. 1998. View Article : Google Scholar : PubMed/NCBI
14	Fardel O, Lecureur V, Daval S, Corlu A and Guillouzo A: Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur J Biochem. 246:186–192. 1997. View Article : Google Scholar : PubMed/NCBI
15	Cheng Q, Lee HH, Li Y, Parks TP and Cheng G: Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-κB inhibition. Oncogene. 19:4936–4940. 2000.PubMed/NCBI
16	Chin KV, Ueda K, Pastan I and Gottesman MM: Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 255:459–462. 1992. View Article : Google Scholar : PubMed/NCBI
17	Synold TW, Dussault I and Forman BM: The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 7:584–590. 2001. View Article : Google Scholar : PubMed/NCBI
18	Bush JA and Li G: Regulation of the Mdr1 isoforms in a p53-deficient mouse model. Carcinogenesis. 23:1603–1607. 2002.
19	Sen R and Baltimore D: Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism. Cell. 47:921–928. 1986.
20	Lin L, DeMartino GN and Greene WC: Cotranslational biogenesis of NF-κB p50 by the 26S proteasome. Cell. 92:819–828. 1998.
21	Schmitz ML and Baeuerle PA: The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B. EMBO J. 10:3805–3817. 1991.PubMed/NCBI
22	Quivy V and Van Lint C: Regulation at multiple levels of NF-κB-mediated transactivation by protein acetylation. Biochem Pharmacol. 68:1221–1229. 2004.
23	Wu M, Lee H, Bellas RE, et al: Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J. 15:4682–4690. 1996.PubMed/NCBI
24	Ryan KM, Ernst MK, Rice NR and Vousden KH: Role of NF-κB in p53-mediated programmed cell death. Nature. 404:892–897. 2000.
25	Pham LV, Tamayo AT, Yoshimura LC, et al: A CD40 signalosome anchored in lipid rafts leads to constitutive activation of NF-κB and autonomous cell growth in B cell lymphomas. Immunity. 16:37–50. 2002.PubMed/NCBI
26	Ueda M, Kokura S, Imamoto E, et al: Blocking of NF-κB activation enhances the tumor necrosis factor α-induced apoptosis of a human gastric cancer cell line. Cancer Lett. 193:177–182. 2003.
27	Wang CY, Mayo MW, Korneluk RG, Goeddel DV and Baldwin AS Jr: NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 281:1680–1683. 1998.
28	Thevenod F, Friedmann JM, Katsen AD and Hauser IA: Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-κB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis. J Biol Chem. 275:1887–1896. 2000.
29	Pallis M, Turzanski J, Higashi Y and Russell N: P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma. 43:1221–1228. 2002. View Article : Google Scholar
30	Ruefli AA, Tainton KM, Darcy PK, Smyth MJ and Johnstone RW: P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ. 9:1266–1272. 2002. View Article : Google Scholar : PubMed/NCBI
31	Turzanski J, Grundy M, Shang S, Russell N and Pallis M: P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway. Exp Hematol. 33:62–72. 2005. View Article : Google Scholar : PubMed/NCBI
32	Schuurhuis GJ, Pinedo HM, Broxterman HJ, van Kalken CK, Kuiper CM and Lankelma J: Differential sensitivity of multi-drug-resistant and -sensitive cells to resistance-modifying agents and the relation with reversal of anthracycline resistance. Int J Cancer. 46:330–336. 1990. View Article : Google Scholar : PubMed/NCBI
33	Ludwig JA, Szakacs G, Martin SE, et al: Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res. 66:4808–4815. 2006. View Article : Google Scholar : PubMed/NCBI
34	Hall MD, Handley MD and Gottesman MM: Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci. 30:546–556. 2009. View Article : Google Scholar : PubMed/NCBI